Nearly 15 years after its last guidance, the ASTCT has dropped a major update on how clinicians should diagnose, grade, and treat acute graft-versus-host disease (GVHD) — one of the most serious complications following allogeneic hematopoietic cell transplantation. The updated recommendations, published in Transplantation and Cellular Therapy, aim to bring consistency to a field where multiple grading systems and evolving therapies have made standardization difficult.

The guidelines back the MAGIC grading system as the new consensus standard, citing its clearer criteria for staging lower GI GVHD and upper GI symptoms. Corticosteroids remain the recommended first-line therapy — a tough standard to beat — while ruxolitinib (Jakafi) is now the consensus second-line option for steroid-refractory disease. Notably, no consensus third-line therapy exists, highlighting a significant unmet need for patients with treatment-resistant disease.

Key Takeaways:

• The MAGIC Algorithm Probability (MAP) is validated for mortality risk stratification but is not yet recommended to guide treatment decisions
• Ruxolitinib has transformed steroid-refractory GVHD care, but a substantial subset of high-risk patients still don't respond
• Third-line therapy remains an open question — rigorous clinical trials in this population are urgently needed

Why it matters: With no major GVHD guidelines update in over a decade, transplant clinicians now have a clearer, evidence-based roadmap. Standardizing grading and treatment approaches could improve patient outcomes and make clinical trial comparisons more meaningful going forward.